Anti-microRNAs as Novel Therapeutic Agents in the Clinical Management of Alzheimer's Disease
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Overview- One hundred and ten years since its first description Alzheimer's disease (AD) still retains its prominent status: (i) as the industrialized world's number one cause of age-related intellectual impairment and cognitive decline; (ii) as this country's most rapidly expanding socioeconomic and healthcare concern; and (iii) as an insidious, progressive and lethal neurological disorder of the human central nervous system (CNS) for which there is currently no adequate treatment or cure (Alzheimer, 1991; Alzheimer et al., 1991, 1995) [https://www.alz.org/facts/downloads/facts_figures_2015.pdf (2015)]. The concept of small non-coding RNAs (ncRNAs) as being involved in the etiopathogenesis of AD and age-related human neurodegenerative disease was first proposed about 25 years ago, however it was not until 2007 that specific microRNA (miRNA) abundance, speciation and localization to the hippocampal CA1 region (an anatomical area of the human CNS specifically targeted by the AD process) was shown to strongly associate with AD-type change when compared to age-matched controls (Lukiw et al., 1992; Lukiw, 2007; Schipper et al., 2007; Cogswell et al., 2008; Guerreiro et al., 2012). Currently about 400 reports address the potential link between disruptions in miRNA signaling and the development of various features associated with AD neuropathology (http://www.ncbi.nlm.nih.gov/pubmed/?term=micro+RNA+alzheimer's+disease). In this "Perspectives" paper we will highlight some of the most recent literature on anti-miRNA (AM; antagomir) therapeutic strategies and some very recent technological advances in the analysis and characterization of defective miRNA signaling pathways in AD compared to neurologically normal age-matched controls.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Baumgart, M., Snyder, H. M., Carrillo, M. C., Fazio, S., Kim, H., & Johns, H. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.05.016 · Cited by 1,660 · cited 2×
“…of the AM (or exogenously added stabilized miRNA) may also be of use in obtaining the most efficacious and sought after pharmacological effect (Sethi and Lukiw, 2009; Monteys et al., 2014; Baumgart et al., 2015; Blennow et al., 2015; Hill and Lukiw, 2015; Sanei and Chen, 2015) (see below).”
BackgroundAn english translation of alzheimer’s 1907 paper, “über eine eigenartige erkankung der hirnrinde”
Stelzmann, R. A., Norman Schnitzlein, H., & Reed Murtagh, F. (1995) · Clinical Anatomy · doi:10.1002/ca.980080612 · Cited by 1,455
Cogswell, J. P., Ward, J., Taylor, I. A., Waters, M., Shi, Y., Cannon, B., Kelnar, K., Kemppainen, J., Brown, D., Chen, C., et al. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-14103 · Cited by 943 · cited 3×
“…potential for unwanted off-target effects using NF-kB inhibitors may be both severe and numerous (Continued) of the brain targeted by the AD process after post-mortem examination, (ii) in blood serum, and (iii) in cerebrospinal fluid (CSF; Lukiw, 2007; Schipper et al., 2007; Cogswell et al., 2008).”
BackgroundResultBrites, D., & Fernandes, A. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00476 · Cited by 599
Altered microRNA profiles in cerebrospinal fluid exosome in Parkinson disease and Alzheimer disease
Gui, Y., Liu, H., Zhang, L., Lv, W., & Hu, X. (2015) · Oncotarget · doi:10.18632/oncotarget.6158 · Cited by 552 · cited 4×
“…LNA-based, nanovesicle and related miRNA delivery systems and the interested reader is encouraged to access and reference these recently compiled volumes (Janssen et al., 2013; Gui et al., 2015; Kang et al., 2015; Properzi et al., 2015; Shi, 2015; Srivastava et al., 2015; van der Pol et al., 2016).”
BackgroundInfluentialColangelo, V., Schurr, J., Ball, M. J., Pelaez, R. P., Bazan, N. G., & Lukiw, W. J. (2002) · Journal of Neuroscience Research · doi:10.1002/jnr.10351 · Cited by 517 · cited 2×
“…in neurodegenerative disorders such as AD may in part explain the large number of brain gene mRNAs that are found to be consistently down-regulated in anatomical regions of the human brain targeted by the AD process (Loring et al., 2001; Colangelo et al., 2002; Lukiw, 2004; Ginsberg et al., 2012).”
BackgroundSelf-citationLukiw, W. J., Zhao, Y., & Cui, J. G. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m805371200 · Cited by 441
Self-citationSethi, P., & Lukiw, W. J. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2009.04.052 · Cited by 409 · cited 6×
“…relatively short half-life (∼1–3 h) of miRNAs in AD tissues and their “reduced presence” under pathophysiological intracellular conditions which promote the rapid degeneration of neuromolecular components (Sethi and Lukiw, 2009; Ramsingh et al., 2010; Hill and Lukiw, 2015; Sanei and Chen, 2015).”
BackgroundSelf-citationThe genetic architecture of Alzheimer's disease: beyond APP, PSENs and APOE
Guerreiro, R. J., Gustafson, D. R., & Hardy, J. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.03.025 · Cited by 285 · cited 2×
“…the hippocampal CA1 region (an anatomical area of the human CNS specifically targeted by the AD process) was shown to strongly associate with AD-type change when compared to age-matched controls (Lukiw et al., 1992; Lukiw, 2007; Schipper et al., 2007; Cogswell et al., 2008; Guerreiro et al., 2012).”
BackgroundResultCui, J. G., Li, Y. Y., Zhao, Y., Bhattacharjee, S., & Lukiw, W. J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.178848 · Cited by 274 · cited 8×
“…prions, and other neurological diseases and other factors; each of these AD-relevant stressors are known induce NF-kB signaling (Lukiw et al., 2008; Cui et al., 2010; Lukiw, 2012a,b, 2013a; Hill et al., 2015b; Srinivasan and Lahiri, 2015; Yuan et al., 2015); NF-kB signaling has been observed to be…”
BackgroundSelf-citationØstergaard, S. D., Mukherjee, S., Sharp, S. J., Proitsi, P., Lotta, L. A., Day, F., Perry, J. R. B., Boehme, K. L., Walter, S., Kauwe, J. S., et al. (2015) · PLOS Medicine · doi:10.1371/journal.pmed.1001841 · Cited by 203
Srinivasan, M., & Lahiri, D. K. (2015) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.989834 · Cited by 164 · cited 7×
“…include the significant enhancement in the transcription of certain brain miRNAs and the inducible up-regulation of their expression by NF-kB (Lukiw and Bazan, 1998; Lukiw et al., 2008; Cui et al., 2010; Lukiw, 2012a,b, 2013a; Devier et al., 2015; Kaur et al., 2015; Srinivasan and Lahiri, 2015).”
BackgroundInfluentialThe regulation of exosome function in the CNS: implications for neurodegeneration
Properzi, F., Ferroni, E., Poleggi, A., & Vinci, R. (2015) · Swiss Medical Weekly · doi:10.4414/smw.2015.14204 · Cited by 62 · cited 3×
“In the last 2 years the use of small, naturally occurring or engineered membrane-enveloped nanovesicles called exosomes represent a novel approach to drug delivery and disease management (Kang et al., 2015; Properzi et al., 2015; Shi, 2015; Srivastava et al., 2015).”
Backgroundvan Harten, A. C., Mulders, J., Scheltens, P., van der Flier, W. M., & Oudejans, C. B. M. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-140075 · Cited by 41
Cited by
The Amyloid-β Pathway in Alzheimer’s Disease
Hampel, H., Hardy, J., Blennow, K., Chen, C., Perry, G., Kim, S. H., Villemagne, V. L., Aisen, P., Vendruscolo, M., Iwatsubo, T., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01249-0 · Cited by 1,952
“MicroRNAs (miRNAs) constitute a large family of small noncoding RNAs that exert an inhibitory effect on gene expression by destabilizing messenger RNAs and inhibiting the translation process [93].”
BackgroundUpstream regulators and downstream effectors of NF-κB in Alzheimer’s disease
Shi, Z.-M., Han, Y.-W., Han, X.-H., Zhang, K., Chang, Y.-N., Hu, Z.-M., Qi, H.-X., Ting, C., Zhen, Z., & Hong, W. (2016) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2016.05.022 · Cited by 125
“In recent efforts to neutralize NF-κB-triggered, miRNA-mediated pathologies, the use of anti-miRNA and anti-NF-κB strategies have worked surprisingly well both in vitro and in vivo in animal experimentation [78,79].”
microRNA‐132: a key noncoding RNA operating in the cellular phase of Alzheimer's disease
Salta, E., & De Strooper, B. (2017) · The FASEB Journal · doi:10.1096/fj.201601308 · Cited by 99
Chromosome 21-Encoded microRNAs (mRNAs): Impact on Down’s Syndrome and Trisomy-21 Linked Disease
Alexandrov, P. N., Percy, M. E., & Lukiw, W. J. (2018) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-017-0514-0 · Cited by 44
“…of essential and homeostatic mRNA and gene expression patterns in DS patients, and/or (ii) may ultimately provide more effective treatments in the clinical management of ancillary maladies associated with the T21 phenotype (Lukiw 2013; Antonarakis 2017; Castro et al. 2017; Zhao et al. 2016).”
Self-citation(2017) · PubMed · Cited by 18
Metadata
- Authors
- Zhao, Y., Alexandrov, P. N., & Lukiw, W. J.
- Venue
- Frontiers in Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2016-02-25
- Volume
- 10
- Pages
- 59-59
- ISSN
- 1662-453X (ISSN-L)
- OpenAlex
- W2334403618
- Cited by
- 30
- References
- 14
- FWCI
- 2.28
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.